Citi Resumes Sensei Biotherapeutics (SNSE) at Buy, 'Initial SNS-101 Efficacy Data at ASCO Suggest Early Clinical Activity'
Tweet Send to a Friend
Citi analyst Samantha Semenkow resumes coverage on Sensei Biotherapeutics (NASDAQ: SNSE) with a Buy rating and a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
